Nightstar Therapeutics (NASDAQ:NITE) – Research analysts at Leerink Swann issued their Q2 2018 earnings per share (EPS) estimates for shares of Nightstar Therapeutics in a report issued on Wednesday, April 11th. Leerink Swann analyst J. Schwartz expects that the company will earn ($0.77) per share for the quarter. Leerink Swann also issued estimates for Nightstar Therapeutics’ Q4 2018 earnings at ($0.88) EPS, FY2018 earnings at ($1.66) EPS and FY2019 earnings at ($1.75) EPS.
Other equities analysts have also recently issued reports about the company. Chardan Capital started coverage on Nightstar Therapeutics in a research report on Wednesday, January 3rd. They issued a “buy” rating and a $40.00 price target for the company. Mizuho started coverage on Nightstar Therapeutics in a research report on Tuesday, February 27th. They issued a “buy” rating and a $20.00 price target for the company. Wedbush reiterated an “outperform” rating and issued a $31.00 price target on shares of Nightstar Therapeutics in a research report on Wednesday, March 7th. Finally, Zacks Investment Research cut Nightstar Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 7th. One analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $28.50.
Shares of NASDAQ NITE opened at $14.55 on Monday. The firm has a market capitalization of $410.26 and a PE ratio of -8.93. Nightstar Therapeutics has a fifty-two week low of $10.01 and a fifty-two week high of $24.93.
Several hedge funds and other institutional investors have recently made changes to their positions in NITE. Nationwide Fund Advisors purchased a new position in shares of Nightstar Therapeutics in the third quarter valued at $1,196,000. Essex Investment Management Co. LLC purchased a new position in shares of Nightstar Therapeutics in the fourth quarter valued at $1,771,000. Finally, Ameriprise Financial Inc. purchased a new position in shares of Nightstar Therapeutics in the third quarter valued at $5,761,000. Institutional investors own 29.06% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of United States & international trademark and copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/17/equities-analysts-issue-forecasts-for-nightstar-therapeutics-q2-2018-earnings-nite.html.
Nightstar Therapeutics Company Profile
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia.
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.